SLC5A2 and diabetic kidney disease: The strengths of this study are that it is the first to demonstrate that SGLT2 inhibitors may reduce proteinuria in patients with diabetes nephropathy potentially by inhibiting renal oxidative stress rather than by AGEs pathway and will not induce RAAS activation.